Inclusion Criteria:

3.1.1 Age > 5 years and < 55 years. NOTE: Subjects ages 5-30 are eligible to be treated
at Cincinnati Children's Hospital Medical Center; subjects over age 30 will be treated at
Ohio State University Comprehensive Cancer Center.

3.1.2 Anticipated life expectancy of at least nine months 3.1.3 Karnofsky score > 50 for
patients > 10 years of age, and Lansky score > 50 for patients < 10 years of age. Patients
who are unable to walk because of paralysis, but who are up in a wheelchair, will be
considered ambulatory for the purpose of assessing the performance score.

3.1.4 Patients must have one of the following newly-diagnosed central nervous system
tumors, confirmed by histologic verification: Glioblastoma multiforme (WHO grade IV) OR
Anaplastic astrocytoma (WHO grade III)

3.1.5 Patients older than 30 years that have undergone a gross total resection and who do
not have measurable disease on post operative MRI; measurable disease as assessed by post
operative MRI is required on patients 30 years of age or younger.

3.1.6 Neurologic deficits and corticosteroid doses must be stable or decreasing at the
time of study entry.

3.1.7 Adequate organ function as defined by: Serum creatinine < upper limit of normal, or
GFR > 70 ml/min/1.73 m2 Total bilirubin < 2.0 mg/dl; SGPT (ALT) AND SGOT (AST) < 2.5x
upper limit of normal; serum albumin > 2.0 g/dL Absolute neutrophil count > 1,000/µl,
platelet count > 75,000/µl independent of transfusions

3.1.8 The patient and/or the patient's legally authorized guardian must give written
informed consent according to local Institutional and/or University Human Experimentation
Committee requirements.

3.1.9 Women or men with reproductive potential must use effective contraception throughout
the study. Effective contraception methods for women would include either an oral or
transdermal contraceptive, injectable contraceptive (e.g., Depo-Provera), or contraceptive
implants (e.g., intrauterine device). All males on study must agree to the use of condoms
during intercourse.

3.1.10 Women of reproductive potential must have a negative serum pregnancy test.

Exclusion Criteria:

3.2.1 Any prior treatment with chemotherapy or radiotherapy.

3.2.2 Any tumor arising in the spine or brainstem.

3.2.3 Presence of metastatic disease in the spine.

3.2.4 WHO grade III oligodendroglioma or oligoastrocytoma.

3.2.5 Active infection at time of study entry.

3.2.6 Pregnant or lactating females are excluded, because of the known teratogenic effects
of alkylating agents.

3.2.7 Known HIV-positive patients. Patients with immune deficiency are at increased risk
of lethal infections when treated with marrow-suppressive therapy and are excluded from
this study. An infectious disease screen consisting of HIV I & II Ab and NAT, HTLV I & II
Ab, RPR, Hepatitis B Surface Ag, Hepatitis B Core Ab and Hepatitis C Ab will be obtained
at study entry.

3.2.8 Concurrent treatment with other investigational anti-cancer agents.

3.2.9 Serious illness or medical condition which would not permit the patient to be
managed according to the protocol.

3.2.10 Low-grade glioma (WHO Grade 1-2).